JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation

NCT05002270 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

29

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor
NSCLC
CRC

Interventions

DRUG: JAB-21822 (KRAS G12C inhibitor)
DRUG: JAB-21822 (KRAS G12C inhibitor)
DRUG: JAB-21822 (KRAS G12C inhibitor)
DRUG: Cetuximab (EGFR inhibitor)

Sponsor

Jacobio Pharmaceuticals Co., Ltd.